MALT1

Back to Biomarkers List

Associated Genetic Biomarkers

Associated Diseases

Overview

Location [1]

18q21.32

Synonyms [1]

MLT, IMD12, PCASP1, MLT1

MALT1 paracaspase (MALT1) is a gene that encodes a protein that may function in NF-kappaB activation. Fusions, missense and silent mutations are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.

Biomarker-Directed Therapies

View Therapies for MALT1

MALT1 is a predictive biomarker for use of chlorambucil and rituximab in patients.

Marginal zone lymphoma and mature B-cell lymphoma/leukemia have the most therapies with MALT1 as a predictive biomarker.

Of the therapies with MALT1 as a predictive biomarker, 0 are FDA-approved in at least one clinical setting and 2 have NCCN guidelines in at least one clinical setting.

BIRC3-MALT1 Fusion is the top alteration on MALT1 targeted by therapies [4].

Chlorambucil + Rituximab +

Marginal Zone Lymphoma -

Biomarker Criteria:

Sample must match all of the following:

BIRC3-MALT1 Fusion

Predicted Response: Primary Sensitivity

Clinical Setting(s): Refractory (NCCN)

Note: Marginal Zone Lymphoma (MZL) is a type of Mature B-Cell Lymphoma. MZL has further subtypes, of which the pulmonary and extranodal MZL of gastric MALT lymphomas frequently carries the t(11;18)(q21;q21) translocation. It is associated with disseminated disease and resistance to antibiotic treatment for H.pylori. The fusion was however associated with improved remission rates in patients treated with a combination of rituximab plus chlorambucil.

Biomarker Criteria: Sample must match all of the following: BIRC3-MALT1 Fusion	Predicted Response: Primary Sensitivity
	Clinical Setting(s): Refractory (NCCN)
	Note: Marginal Zone Lymphoma (MZL) is a type of Mature B-Cell Lymphoma. MZL has further subtypes, of which the pulmonary and extranodal MZL of gastric MALT lymphomas frequently carries the t(11;18)(q21;q21) translocation. It is associated with disseminated disease and resistance to antibiotic treatment for H.pylori. The fusion was however associated with improved remission rates in patients treated with a combination of rituximab plus chlorambucil.

Mature B-Cell Lymphoma/Leukemia -

Biomarker Criteria:

Sample must match all of the following:

BIRC3-MALT1 Fusion

Predicted Response: Primary Sensitivity

Clinical Setting(s): Refractory (NCCN)

Note: A subtype of Mature B-Cell Lymphoma is Marginal Zone Lymphoma (MZL). MZL has further subtypes, of which the pulmonary and extranodal MZL of gastric MALT lymphomas frequently carries t(11;18)(q21;q21) translocation. It is associated with disseminated disease and resistance to antibiotic treatment for H.pylori. The fusion was however associated with improved remission rates in patients treated with a combination of rituximab plus chlorambucil.

Biomarker Criteria: Sample must match all of the following: BIRC3-MALT1 Fusion	Predicted Response: Primary Sensitivity
	Clinical Setting(s): Refractory (NCCN)
	Note: A subtype of Mature B-Cell Lymphoma is Marginal Zone Lymphoma (MZL). MZL has further subtypes, of which the pulmonary and extranodal MZL of gastric MALT lymphomas frequently carries t(11;18)(q21;q21) translocation. It is associated with disseminated disease and resistance to antibiotic treatment for H.pylori. The fusion was however associated with improved remission rates in patients treated with a combination of rituximab plus chlorambucil.

Significance of MALT1 in Diseases

Marginal Zone Lymphoma +

Mature B-Cell Lymphoma/Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Biomarkers /